GlassScriptPhysician profile
Alexander Belkin
NPI 1346701653
$5,524.96
in general payments reported to CMS, 2019-2025
22 companies · $469 in 2025
The $469 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,172 · 2023: $2,167 · 2024: $1,716 · 2025: $469.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,924 · Education: $429.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,923.95 |
| Education | $428.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $856.36 | 2022-2024 | Jakafi |
| Janssen Scientific Affairs, LLC | $691.77 | 2022-2025 | Darzalex, Imbruvica, Tecvayli |
| Janssen Biotech, INC. | $567.98 | 2023-2024 | Darzalex, Tecvayli, Carvykti |
| E.R. Squibb & Sons, L.L.C. | $557.98 | 2022-2025 | Reblozyl, Pomalyst, Opdivo |
| Kite Pharma, INC. | $454.43 | 2023-2025 | Yescarta |
| Rigel Pharmaceuticals, INC. | $394.28 | 2022-2025 | Rezlidhia, Tavalisse, Gavreto |
| Abbvie INC. | $382.56 | 2023-2024 | Epkinly, Venclexta |
| Pharmacyclics LLC, An Abbvie Company | $241.92 | 2023 | Imbruvica |
| Astrazeneca Pharmaceuticals LP | $234.41 | 2022-2024 | Tagrisso |
| Genzyme Corporation | $133.34 | 2023 | |
| Progenics Pharmaceuticals, INC. | $121.07 | 2023 | Pylarify |
| Seagen INC. | $119.36 | 2023 | Adcetris |
| Takeda Pharmaceuticals U.S.A., INC. | $106.03 | 2022 | |
| Gilead Sciences, INC. | $103.67 | 2023 | Trodelvy |
| Eisai INC. | $100.34 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adc Therapeutics America, INC. | $99.39 | 2022 | |
| Sanofi-Aventis U.S. LLC | $95.07 | 2024 | |
| Sobi, INC | $92.07 | 2024 | |
| Beigene USA, INC. | $90.80 | 2023 | Brukinsa |
| Amgen INC. | $38.60 | 2023 | Lumakras, Nplate, Xgeva |
| Array Biopharma INC | $25.10 | 2025 | Mektovi, Braftovi, Tukysa |
| Shield Therapeutics INC | $18.43 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Belkin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.